Q3 2025 Autolus Therapeutics PLC Earnings Call Transcript
Key Points
- Autolus Therapeutics PLC (AUTL) achieved market leadership and broad market access for OCASL in the US within the first nine months of its launch.
- The company reported net sales of $21.1 million in the third quarter, with a total of $51 million in sales for the first nine months of 2025.
- AUTL has authorized 60 treatment centers across the US, achieving patient access for more than 90% of US covered lives.
- The manufacturing success rate for OCASL is well above 90%, indicating a reliable product supply.
- The company is expanding its pipeline with ongoing clinical trials in pediatric ALL, lupus nephritis, and progressive multiple sclerosis.
- The cost of sales in the third quarter was $28.6 million, which is higher than the net product revenue, indicating a need for improved cost management.
- AUTL reported a net loss of $79.1 million for the third quarter, although this was a slight improvement from the previous year.
- There is uncertainty regarding the impact of seasonality and holidays on sales performance in the fourth quarter.
- The company faces challenges in optimizing its operations and improving overall margins and efficiencies.
- AUTL's cash and marketable securities decreased from $588 million at the end of December 2024 to $367.4 million at the end of September 2025, primarily due to net cash use in operating activities.
Good day.
Thank you for standing by. Welcome to Adoli Therapeutic's 3rd quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising Johannes raised. Please note that today's conference is being recorded.
I will now hand the conference over to your first speaker, Amanda Cray, executive director of investor relations. Please go ahead.
Thank you, Olivia. Good morning or good afternoon, everyone, and thank you for joining us on today's call. With me, our Chief Executive Officer, Doctor Christian Eitan, and Chief Financial Officer Rob Dolsky.
I'd like to remind you that during today's call, we will make statements related to our business that are forward-looking under federal
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
